Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
about
Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.The role of HIV and monocytes/macrophages in adipose tissue biologyHIV infection.Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients.Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.Mitochondrial toxicity and HIV therapy.Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature.Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.Strategies for treating HIV-related lipodystrophy.Switch studies: a review.Pathogenesis and treatment of human immunodeficiency virus lipodystrophyAntiretroviral therapies associated with lipoatrophy in HIV-infected womenFat distribution in women with HIV infection.Fat distribution in men with HIV infection.The metabolic effects of lopinavir/ritonavir in HIV-negative menThe effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot studyThe study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristicsContribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsDepot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophyNew and emerging agents in the management of lipodystrophy in HIV-infected patients.Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.Treatment of HIV infection in the older patient.HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact.Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.HIV-associated lipodystrophy syndrome: A review of clinical aspects.Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.Antiretroviral therapy associated mastopathy.People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study.HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.Toxic metabolic syndrome associated with HAART.Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy.Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy statusIndependent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women.Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort StudyLipoatrophy and lipohypertrophy are independently associated with hypertensionEpidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly.The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population.Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virusChanges in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen.
P2860
Q31055878-A375D5D5-4C4F-42B4-A28D-5414B77F6FFDQ33608155-5BA2A47B-F92E-4264-B1C7-A0B8EAA502B7Q34011172-E57BDFEC-1765-435B-AD43-7C838182C94BQ34024617-85294BC9-E513-42B0-A1AA-C1BB54215533Q34187120-40B38D5E-9214-4345-B423-4C52D03626E2Q34279271-5A3A67E4-D80B-4E4F-BC61-A03BF511904BQ34341008-2076A65E-E0F7-4BA4-B50D-DD30B000C505Q34461377-E1A688CE-A62C-44F8-8D03-FD4F067B6DD3Q34481623-8ED9B2A3-8FB9-49D2-B49F-8F091CCCF734Q34636824-EE94F88D-43A1-4D17-803C-178188D86A45Q34639290-19DE4B2F-0500-4A87-9E59-50BF584BA8C5Q35097650-B2A6C619-3C59-46DF-A313-F2D5AF180C93Q35194384-65A04C94-4AAF-4EB0-8B38-52D0EA24BA24Q35194387-CC4AD5C0-EBD0-4689-9660-F905570F0E91Q35194394-2755154C-CFB1-4C2C-A848-0B32F23D64B9Q35206621-753590DB-319C-4ADF-9011-BAFBF7DBE11EQ35206623-D3BD0D2D-B951-430D-B9FB-188FC2235140Q35206635-62CE196A-47D6-45E8-88C6-FC3D4F29E273Q35400307-39A258CB-26B3-4B7E-9D3E-6AFF67D50A46Q35557229-92CA06C8-0DF1-4490-AC1E-47CB09F23131Q35644326-31E2208D-B4D5-4556-940D-3FBA051BEA07Q35917538-2A3599FE-5955-4943-81B8-5A7D72824424Q36007239-995F8921-08ED-4451-A819-4D1E83E2E5F6Q36081993-0295385B-9036-4272-8823-FE0632E48763Q36171069-22DB3596-1CD5-4D30-8837-83D514679F9DQ36206201-CC9B3785-5B0C-4935-B19B-883C61A51161Q36233724-D3E8BEE9-7E3D-4EE6-8384-DA30C93A6BD1Q36249550-039F2237-5C53-44CA-A66B-1798A8484D91Q36441515-E7AC148B-3197-46F1-8EE2-A82A9FD63EB6Q36544924-C7202B04-9DC1-4C28-BDDE-27019A34BA8AQ36616941-8AAE1993-698B-47E2-ACC4-01255F47C0E2Q36951647-C2DB1B74-38A3-41E9-9CEA-C6B391DA6B17Q37114196-36905B94-2ECF-4007-B73B-481BDED4DC00Q37161855-57344647-263E-49E9-9878-F653DFA656C5Q37203062-8B9DB19B-6595-452C-AACD-CF66F84B00E6Q37311726-0CD570EC-61EB-468E-9512-4DE2D7BFB073Q37419826-D3FEA7AF-AFC7-4459-A0F0-D49756C598B6Q37436597-19A8BE56-D302-46AD-967E-269F05C200BBQ37443914-70FDBFC4-CFFD-453F-B571-580C05586B23Q37705891-4B12A6EB-E50B-4F7A-95C8-35E6E710D873
P2860
Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Fat distribution evaluated by ...... y results of the LIPOCO study.
@en
Fat distribution evaluated by ...... y results of the LIPOCO study.
@nl
type
label
Fat distribution evaluated by ...... y results of the LIPOCO study.
@en
Fat distribution evaluated by ...... y results of the LIPOCO study.
@nl
prefLabel
Fat distribution evaluated by ...... y results of the LIPOCO study.
@en
Fat distribution evaluated by ...... y results of the LIPOCO study.
@nl
P2093
P1433
P1476
Fat distribution evaluated by ...... y results of the LIPOCO study.
@en
P2093
Avellaneda R
Gastaut JA
Partisani M
Poizot-Martin I
Saint-Marc T
Touraine JL
P356
10.1097/00002030-200001070-00005
P407
P577
2000-01-01T00:00:00Z